Evotec
Oliver Philps is a seasoned professional in medicinal chemistry with extensive experience spanning over two decades in various roles within the pharmaceutical industry. Currently serving as a Featured Reviewer/Author and Content Creator at Drughunter.com since November 2023, Oliver previously held a Senior Scientist position at Evotec, making significant contributions to the progression of client lead molecules into pre-clinical studies. Academic involvement includes a tenure as a Visiting Lecturer in Medicinal Chemistry at Oxford University, where Oliver delivered lectures across multiple therapeutic areas. Earlier career achievements include roles at leading companies such as Eisai and GlaxoSmithKline, focusing on CNS projects and drug development efforts. Oliver earned a PhD in Medicinal Chemistry from the University of Sussex, along with additional qualifications in plumbing from North Hertfordshire College.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.